In a landmark editorial published on March 10, 2026, in Volume 18 of Aging-US, David A. Barzilai, a prominent figure affiliated with Geneva College of Longevity Science, Healthspan Coaching LLC, and Harvard Medical School, presents a compelling argument for redefining the primary objectives of geroscience. The editorial, titled “Healthy life extension: Geroscience’s north star,” calls for a paradigm shift in aging research, emphasizing the critical importance of prioritizing health-adjusted longevity over the traditional, often competing, goals of lifespan and healthspan extension.
Barzilai pays homage to the late Mikhail Blagosklonny, whose pioneering work laid the foundation for many concepts in aging biology. Building on this legacy, the editorial argues that the field of geroscience must coalesce around the unified goal of extending healthy life rather than merely adding years to human life. Instead of treating lifespan extension and healthspan as separate or conflicting aims, researchers should integrate these concepts, focusing on increasing the years lived in good health, free from chronic diseases and functional decline.
A central theme of the editorial is the need to utilize robust clinical and preclinical endpoints that meaningfully reflect improvements in healthspan. Barzilai stresses the significance of measurable outcomes such as health-adjusted life expectancy (HALE) and quality-adjusted life years (QALYs), which provide a more comprehensive understanding of longevity by incorporating functional capacity, resilience, and independence. This approach transcends traditional reliance on biomarkers alone, promoting a more holistic assessment of aging interventions’ real-world impact.
The editorial comprehensively reviews empirical data demonstrating that while human life expectancy has steadily increased over recent decades, the extension of healthy, disease-free years has not kept pace. This disparity highlights a significant clinical and societal challenge—individuals are living longer, but often with multiple chronic illnesses and diminished quality of life. Such trends reinforce the imperative for aging research to shift its focus toward strategies that delay the onset of multimorbidity and preserve physiological function.
Barzilai illustrates the potential of targeting conserved molecular pathways that regulate aging by highlighting replicable lifespan enhancements in mammals. Notably, interventions such as rapamycin administration in mice have consistently demonstrated substantial lifespan gains. Moreover, emerging evidence from early human studies indicates that modulating pathways like mammalian target of rapamycin (mTOR) can yield clinically relevant benefits, such as enhanced immune responses to influenza vaccination in older adults, offering promising translational potential.
Despite these encouraging findings, the editorial acknowledges the practical challenges facing the field. Human clinical trials aspiring to validate aging-targeting therapies require rigorous, meaningful endpoints that extend beyond biomarkers to reflect delayed disease onset, preserved functional ability, and sustained resilience against age-associated stressors. These challenges underscore the need for well-designed, long-term studies tailored to capture the complexities of aging biology and functional outcomes relevant to individuals’ quality of life.
Barzilai makes a clarion call for a “moonshot”-level investment in aging biology, urging expanded funding for fundamental research, large-scale clinical trials with clearly defined endpoints in health-adjusted survival, and enhanced translational pipelines capable of bridging robust mammalian lifespan findings to human application. This ambitious commitment aims to accelerate the field’s capacity to develop interventions that realistically extend both lifespan and healthspan in populations worldwide.
The editorial underscores the critical importance of reproducibility and consistency in mammalian lifespan studies as foundational evidence supporting clinical translation. By establishing reliable, replicable data in mammal models, researchers can generate the rigorous scientific basis necessary to justify human trials. Concurrently, the integration of human endpoints that accurately measure independent living and functional resilience will provide the clinical relevance crucial for regulatory and therapeutic success.
Barzilai eloquently emphasizes that geroscience should unequivocally endorse healthy life extension as its raison d’être, advocating to end the false dichotomy that lifespan and healthspan are competing or mutually exclusive goals. Instead, the community must embrace the concept that prolonging life must inherently equate to augmenting the quality of those additional years, thereby fundamentally shifting research priorities, funding mechanisms, and public health strategies.
In closing, the editorial commits to advancing Dr. Blagosklonny’s visionary legacy by positing healthy life extension as the definitive guiding principle for aging research. This “north star” philosophy seeks to restore hope and clarify purpose within the aging biology community, galvanizing researchers, clinicians, and policymakers to align their efforts toward delivering more years of vibrant, functional life to humanity.
Ultimately, Barzilai’s editorial heralds a transformative moment for geroscience. It identifies a clear, measurable objective—extending health-adjusted survival—that promises to redefine success in aging research. By weaving together rigorous science, translational ingenuity, and a renewed focus on quality of life, the field stands poised to revolutionize how society approaches aging, chronic disease, and longevity in the coming decades.
This visionary call-to-action invites the global research community to recognize that the quest for longevity is not simply about adding numbers to the calendar. Instead, it is a profound mission to empower individuals to live longer, healthier, and more independent lives—reframing aging science as a pivotal cornerstone for future medicine and public health.
Subject of Research: Not applicable
Article Title: Healthy life extension: Geroscience’s north star
News Publication Date: 10-Mar-2026
Web References: https://doi.org/10.18632/aging.206359
References: https://doi.org/10.18632/aging.206359
Image Credits: Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Tags: aging biology advancementsbiomedical aging research trendschronic disease prevention agingfunctional decline preventiongeroscience healthy life extensionhealth-adjusted life expectancy metricshealth-adjusted longevity researchhealthspan clinical endpointslifespan vs healthspan integrationlongevity science paradigm shiftMikhail Blagosklonny legacyquality-adjusted life years aging
